Clinical Trial of Vaporized CANNABIS for

Chronic Pain Caused By Sickle Cell Disease

This UCSF study at San Francisco General Hospital (SFGH) will evaluate whether using vaporized cannabis reduces pain in people who are taking opioid medications for chronic pain associated with sickle cell disease.

TO JOIN THIS STUDY YOU MUST:

• Have a diagnosis of sickle cell disease
• Be taking a stable regimen of pain medications, including an opioid (such as morphine, oxycodone, hydromorphone, etc.) for chronic sickle cell disease-associated pain.
• Be able and willing to spend two separate periods of 5 days and 4 nights in the Clinical Research Center at SFGH.
• Have smoked cannabis on at least 6 occasions in your lifetime
• NOT use cannabis for one week prior to starting the study.
• Agree to use adequate birth control during this study.
• NOT be pregnant or breast-feeding, if you are a women who can become pregnant.  You will be tested for pregnancy at screening.
• Be able to read and speak English.
• NOT have any severe heart, lung, kidney, or liver problems.
• NOT currently be using smoked tobacco products.
• NOT test positive for alcohol or injection drugs, as determined by urine screening.
• Meet certain other criteria.

.

IF YOU ARE ELIGIBLE YOU WILL:

• Spend two 5-day periods in a clinical research center at SFGH
• Have blood tests and other measurements done
• Inhale cannabis three times a day, using the VOLCANO™ vaporizer.
• Keep a pain diary for 5 days prior to both hospitalizations to track your pain and medication use

You can receive up to $560.00 for participating.

FOR MORE INFORMATION CALL (415) 476-4082 ext. 146

DIVISION OF HEMATOLOGY-ONCOLOGY, UCSF MEDICAL SERVICE AT SAN FRANCISCO GENERAL HOSPITAL

UNIVERSITY OF CALIFORNIA SAN FRANCISCO

CHR #13-10526